SCPX Stock Overview
Through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Scorpius Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.89 |
| 52 Week High | US$140.00 |
| 52 Week Low | US$0.73 |
| Beta | -0.21 |
| 11 Month Change | -82.70% |
| 3 Month Change | -96.23% |
| 1 Year Change | -99.33% |
| 33 Year Change | -99.93% |
| 5 Year Change | -99.88% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Dec 28
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Sep 02Heat Biologics names Anthony Manning as chief scientific advisor
May 10Heat Biologics EPS misses by $0.01, misses on revenue
May 05We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely
Apr 30Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years
Mar 07Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Jan 13
Shareholder Returns
| SCPX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.2% | 0.1% | 0.06% |
| 1Y | -99.3% | 13.8% | 22.6% |
Return vs Industry: SCPX underperformed the US Biotechs industry which returned 13.8% over the past year.
Return vs Market: SCPX underperformed the US Market which returned 22.6% over the past year.
Price Volatility
| SCPX volatility | |
|---|---|
| SCPX Average Weekly Movement | 63.3% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SCPX's share price has been volatile over the past 3 months.
Volatility Over Time: SCPX's weekly volatility has increased from 36% to 63% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 83 | Jeff Wolf | www.scorpiusbiologics.com |
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services.
Scorpius Holdings, Inc. Fundamentals Summary
| SCPX fundamental statistics | |
|---|---|
| Market cap | US$2.77m |
| Earnings (TTM) | -US$29.57m |
| Revenue (TTM) | US$9.85m |
0.3x
P/S Ratio-0.1x
P/E RatioIs SCPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCPX income statement (TTM) | |
|---|---|
| Revenue | US$9.85m |
| Cost of Revenue | US$19.69m |
| Gross Profit | -US$9.84m |
| Other Expenses | US$19.73m |
| Earnings | -US$29.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.49 |
| Gross Margin | -99.98% |
| Net Profit Margin | -300.35% |
| Debt/Equity Ratio | 12.3% |
How did SCPX perform over the long term?
See historical performance and comparison